TY - JOUR T1 - Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02341-2018 SP - 1802341 AU - Joseph Jacob AU - Brian J. Bartholmai AU - Coline H.M. van Moorsel AU - Srinivasan Rajagopalan AU - Anand Devaraj AU - Hendrik W. van Es AU - Teng Moua AU - Frouke T. van Beek AU - Ryan Clay AU - Marcel Veltkamp AU - Maria Kokosi AU - Angelo de Lauretis AU - Eoin P. Judge AU - Teresa Burd AU - Tobias Peikert AU - Ronald Karwoski AU - Fabien Maldonado AU - Elisabetta Renzoni AU - Toby M. Maher AU - Andre Altmann AU - Athol U. Wells Y1 - 2019/01/01 UR - http://erj.ersjournals.com/content/early/2019/05/20/13993003.02341-2018.abstract N2 - The advent of antifibrotic agents [1, 2] as standard of care in idiopathic pulmonary fibrosis (IPF) requires that new non-inferiority IPF drug trials will need to identify smaller declines of forced vital capacity (FVC). Marginal annualised FVC declines (between 5.00 and 9.99%) are particularly challenging to interpret as they might reflect measurement variation or genuine clinical deterioration [3]. Following on from previous baseline-only CT analyses [4], the current study examined whether changes in computer features (CALIPER) across serial CT examinations could be considered as a trial co-endpoint, particularly with regard to adjudicating marginal FVC declines, and therefore improve the sensitivity of IPF drug trials.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Jacob reports personal fees from Boehringer Ingelheim, outside the submitted work.Conflict of interest: Dr. Bartholmai reports grants from Royal Brompton Hospital, personal fees from Promedior, personal fees from Boehringer Ingelheim, during the conduct of the study; other from Imbio, LLC, outside the submitted work; In addition, Dr. Bartholmai has a patent SYSTEMS AND METHODS FOR ANALYSING IN VIVO TISSUE VOLUMES USING MEDICAL IMAGING DATA licensed to Imbio, LLC.Conflict of interest: Dr. van Moorsel has nothing to disclose.Conflict of interest: Dr. RAJAGOPALAN reports grants from , Royal Brompton Hospital, during the conduct of the study; other from Imbio, LLC, outside the submitted work; In addition, Dr. RAJAGOPALAN has a patent SYSTEMS AND METHODS FOR ANALYSING IN VIVO TISSUE VOLUMES USING MEDICAL IMAGING DATA licensed to Imbio, LLC.Conflict of interest: Dr. Devaraj reports personal fees from Boehringer Ingelheim, personal fees from Roche, outside the submitted work.Conflict of interest: Dr. van Es has nothing to disclose.Conflict of interest: Dr. Moua has nothing to disclose.Conflict of interest: Dr. van Beek has nothing to disclose.Conflict of interest: Dr. Clay has nothing to disclose.Conflict of interest: Dr. Veltkamp has nothing to disclose.Conflict of interest: Dr. Kokosi has nothing to disclose.Conflict of interest: Dr. De Lauretis has nothing to disclose.Conflict of interest: Dr. Judge has nothing to disclose.Conflict of interest: Dr. Burd has nothing to disclose.Conflict of interest: Dr. Peikert has nothing to disclose.Conflict of interest: Dr. Karwoski reports grants from Royal Brompton Hospital, during the conduct of the study; other from Imbio, LLC, outside the submitted work; In addition, Dr. Karwoski has a patent SYSTEMS AND METHODS FOR ANALYSING IN VIVO TISSUE VOLUMES USING MEDICAL IMAGING DATA licensed to Imbio LLC.Conflict of interest: Dr. Maldonado has nothing to disclose.Conflict of interest: Dr. Renzoni reports personal fees from Roche, personal fees from Boehringher, personal fees from Takeda, outside the submitted work.Conflict of interest: Dr. Maher reports other from Gilead, grants and personal fees from GSK, grants from Novartis, personal fees from Boehringer Ingelheim, personal fees from GSK, personal fees from InterMune, personal fees from Lanthio, personal fees from Sanofi Aventis, grants, personal fees and non-financial support from UCB, personal fees from Astra Zeneca, personal fees from Roche, personal fees from Bayer, personal fees from Biogen Idec, personal fees from Cipla, personal fees from Prometic, personal fees from Apellis, outside the submitted work.Conflict of interest: Dr. Altmann has nothing to disclose.Conflict of interest: Dr. Wells reports personal fees from Intermune, personal fees from Boehringer Inlgeheim, personal fees from Gilead, personal fees from MSD, personal fees from Roche, personal fees from Bayer, personal fees from Chiesi, outside the submitted work. ER -